TRANSCENTA-B (06628) announced that its senior leadership team, including Dr. Xueming Qian, Founder, Chairman, and Chief Executive Officer; Mr. Weiwei Liang, Senior Vice President of Business Development & Corporate Strategy and Interim Chief Financial Officer; and Mr. Tyler Marciniak, Senior Vice President of Capital Markets, Investor Relations & Corporate Communications, will attend the Oppenheimer 36th Annual Healthcare Life Sciences Conference, taking place from February 25 to 26, Eastern Time. The company's virtual presentation is scheduled for 12:00 PM Eastern Time on February 26, 2026. During the conference, management will discuss the strategic achievements for 2026 and provide updates on ongoing business development and operational excellence initiatives.
Key updates include the following: Following the successful execution of a strategic collaboration and non-exclusive technology license agreement with TAIROGEN BIOTECHNOLOGY CORP. in December 2025, the company has now received the upfront payment associated with this collaboration. Subsequent to the update provided in January, the company has engaged in advanced discussions with multiple global and regional pharmaceutical companies regarding the development and commercialization of its core assets. Several parties are currently conducting due diligence and/or are in the contract signing or term sheet negotiation phase for collaborations covering global and regional scopes. The company has also attracted interest from global and regional investment institutions, with several currently in active contract signing or term sheet negotiations for financing related to the company and multiple assets.
Resource integration measures have been implemented, resulting in (i) an approximate 16% reduction in headcount as of December 31, 2025, compared to December 31, 2024, and (ii) an approximate 34% reduction in labor, R&D, and other operating expenses as of December 31, 2025, compared to the same date in 2024. These measures led to estimated cost savings of approximately RMB 19 million in the fourth quarter of 2025 compared to the fourth quarter of 2024, thereby improving operational efficiency and extending the company's cash runway.
The company successfully reached agreements with three suppliers for repayment extensions and/or revised schedules, totaling approximately RMB 10 million, with payment dates extended by an average of over 130 days. These actions were implemented as part of the company's ongoing liquidity and working capital management measures following a disclaimer of opinion, helping to improve short-term cash flow while ensuring uninterrupted operations.
Furthermore, the company maintains strong relationships with banking partners to support the renewal and extension of loan facilities. Since the last update in October 2025, the company has renewed bank financing of RMB 77 million, secured new financing of RMB 15 million, and is in discussions with three other financial institutions regarding additional credit facilities. These measures, if completed, are expected to enhance the company's capital flexibility and support daily operations and R&D expenditures.
Comments